Disc Medicine Inc at American Society of Hematology Meeting Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Ben Burnett - Stifel Nicolaus and Company, Incorporated - Analyst : Okay, great. I'll be the first to say congrats on these updates. It's -- this is very exciting. I thought it was interesting how on the DISC-0974 section in the myelofibrosis presentation that you're kind of outlining three different groups of patients. I was wondering if maybe you could just kind of talk about the kind of what are the regulatory hurdles that you see in each of those different categories?

Question: Ben Burnett - Stifel Nicolaus and Company, Incorporated - Analyst : Apologies. Go ahead, John.

Question: Ben Burnett - Stifel Nicolaus and Company, Incorporated - Analyst : I just wanted to ask one other question around the bitopertin EPP program. So I understand that there's going to be an update in a meeting next year. And I think you kind of talked about how that discussion will be around the confirmatory study. But I guess, is there any further clarification needed on using PPIX as a surrogate endpoint?

Question: Ben Burnett - Stifel Nicolaus and Company, Incorporated - Analyst : Okay, excellent. All right, thanks so much. I appreciate it.

Question: Roger Song - Jefferies Group LLC - Analyst : Great, and my congratulations for the successful ASH updates. So maybe a couple questions from us focusing on the anemia myelofibrosis. Maybe the first one is, very good. You have the data from the JAK versus non-JAK. So just curious mechanistically, how do you think 0974 going to combine with other upcoming MF therapy? How likely they can add additional anemia benefit on top of the other myelofibrosis drug, which are not specifically addressing anemia? Thank you.

Question: Roger Song - Jefferies Group LLC - Analyst : Got it. Yeah, that's helpful. And then another one is just follow-up the previous question related to a different category for the myelofibrosis anemia. And you mentioned clinical meaningful benefit, can you just elaborate on that point? How do you -- how should we think about the clinical meaningfulness given this potentially can be an adjunct therapy on top of the future MF standard of care? Thank you.

Question: Roger Song - Jefferies Group LLC - Analyst : Got it. Thank you. Last question from us is related to the EPP. Maybe any updated thoughts as well or any kind of additional feedback from the FDA in terms of how much confirmatory study enrollment immediately before you can file for accelerated approval and then even the final approval? Thank you.

Question: Roger Song - Jefferies Group LLC - Analyst : Excellent. Thank you. That's from us.

Question: Thomas Smith - Leerink Partners LLC - Analyst : Hey, guys. Thanks for taking the questions, and let me add my congrats on the updates. It just one on 0974 and myelofibrosis. I think you had some patients in the Phase 1b study that were on background, pacritinib and momelotinib. And I believe this came up during the Q&A at the ASH presentation, but did you just comment on any responses seen in these patients and your expectations for the exploratory cohort in Phase 2? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. DECEMBER 09, 2024 / 2:00AM, IRON.OQ - Disc Medicine Inc at American Society of Hematology Meeting

Question: Thomas Smith - Leerink Partners LLC - Analyst : Understood, that makes sense. And then we saw the preclinical data for 0974 in anemia and IBD. I just wondering if you could elaborate a little bit more on how you're thinking about indication expansion for 0974. Any updated thoughts on how you plan to select across a number of anemias of inflammation here? Any thoughts on potential timing for moving into other indications?

Question: Thomas Smith - Leerink Partners LLC - Analyst : Got it, that makes sense. And then maybe just one, last one just for a bitopertin in EPP, and I appreciate the data updates here. Just wondering if you could elaborate on some of the ongoing pre-commercial activities, and specifically with respect to payer engagement, I guess, how much payer engagement you've undertaken to date and how -- if you have any updated thoughts on potential pricing and in the indication like EPP?

Question: Thomas Smith - Leerink Partners LLC - Analyst : Understood that makes sense. Thanks for taking the questions, guys. Congrats again.

Question: Evan Seigerman - BMO Capital Markets - Analyst : Hi, guys. Thank you so much for taking your questions, and my congrats on the data as well. I want really on the CKD program. I'm looking at slides from EHA to now and I've noticed that the timing for the Phase 2a top-line data seem to have slipped a bit. Can you walk me through what's happening there? That seems to be a pretty important program. And with this timeline are things being deprioritized, maybe help us understand kind of how to think about this.

Question: Evan Seigerman - BMO Capital Markets - Analyst : Okay, I guess, maybe asked another way. I guess, what was the cause for the change in timing from June to now? Is it just enrollment, complexities of the trial? I'm just trying to understand what some of the factors behind this were.

Question: Evan Seigerman - BMO Capital Markets - Analyst : Okay. That's very helpful. And then just on, was it 3405, we had some competitive [SIRNA] data presented at the meeting today, maybe walk me through how you see the space evolving clearly a lot of activity of different types of modalities, but this is -- there's a lot of enthusiasm around this. Maybe talk me through the competitive dynamics you see? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. DECEMBER 09, 2024 / 2:00AM, IRON.OQ - Disc Medicine Inc at American Society of Hematology Meeting

Question: Evan Seigerman - BMO Capital Markets - Analyst : Great. Thank you so much for the call there.

Question: Jeffrey Hung - Morgan Stanley - Analyst : Congratulations on the progress, and thanks for taking my questions. From 0974, you indicated that you're starting with the 50 milligrams in the Phase 2 study. Can you just talk about the rationale for starting at 50 milligrams versus 75 milligrams or 100 milligrams? And is there an option built in for patients to increase the dose while on treatment? And if so, how high could they go, or if not, like what is the high dose that you're studying? And then I have a follow-up.

Question: Jeffrey Hung - Morgan Stanley - Analyst : Great. And then for the 0974 Phase 1b data, how were the major responses distributed over doses? Was there a dose-dependent relationship? And then for those who did not experience a response, were there any consistent themes that you saw that could predict why they didn't respond? Like would it be possible that some of those would actually respond with a higher dose of 0974, particularly if they were on a lower dose like 28 milligrams? Thanks.

Question: Jeffrey Hung - Morgan Stanley - Analyst : Thank you.

Question: Kristen Kluska - Cantor Fitzgerald - Analyst : Hi, everyone. Congrats on all the updates at ASH. Had some on 0974. So for the three buckets that you laid out as it relates to transfusion dependence, how would you roughly split these three groups on prevalence in real life? And then as a second part, how might physicians access willingness or ability to lower transfusions and what would be considered meaningful for them, especially as these transfusions only get higher with longer and longer follow-up?

Question: Kristen Kluska - Cantor Fitzgerald - Analyst : Thank you.

Question: David Nierengarten - Wedbush Securities Inc. - Analyst : Hi. This is David Nierengarten on for Martin. So I had a couple of questions mechanistically just on 0974. What do you think is causing the improvements or changes in white blood cell count for anemias of inflammation in the model? I'm just curious if there's a mechanistic explanation. Then similarly, for 3405 and sickle cell, when you talk about changes in sickling hemoglobin and the model, is that -- do you -- what is the mechanism for that besides just like reducing red cell counts? Thanks.

Question: David Nierengarten - Wedbush Securities Inc. - Analyst : Got it. Thanks.

Question: Rami Katkhuda - LifeSci Capital - Analyst : Hey, guys. Congrats on the update, and thanks for taking my questions as well. Just a couple quick ones. I guess, first ,is there any hypothesis as to why the diarrhea rates with 0974 increase from the EHA updates now? And is the AE transient or does it last through the duration of treatment here?

Question: Rami Katkhuda - LifeSci Capital - Analyst : Got it, fair enough. And then as you look to expand into other anemias of inflammation, when do you think your long acting anti-hemojuvelin antibody could come online?

Question: Rami Katkhuda - LifeSci Capital - Analyst : Got it. Thank you, guys. And congrats again.

Question: Douglas Tsao - H.C. Wainwright & Co. - Analyst : Hi, good evening. Thanks for taking the questions. Just maybe first on bitopertin. Obviously, good to see the data in adolescents. I'm just curious when you think about the potential for accelerated approval, would you anticipate you would have labeling to include those patients? And I assume that's like down to age 12?

Question: Douglas Tsao - H.C. Wainwright & Co. - Analyst : Okay, great. Thanks. And in terms of 0974, you mentioned considering doing a basket study. I guess, maybe John, maybe some thoughts on the value -- or the pros and cons of pursuing a basket study versus identifying an indication, one or two indications that you would potentially pursue. Thank you.

Question: Douglas Tsao - H.C. Wainwright & Co. - Analyst : Okay, great. Thank you.

Question: Teraesa Vitelli - Scotiabank - Analyst : Hi. This is Teresa Velli on for Greg Harrison. Congrats on all of the progress, and thanks for taking my question. Just a quick one on bitopertin and the APOLLO study. Would timeline -- would time and sunlight be averaged across the entire treatment period or just one month, once six months of treatment has occurred? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. DECEMBER 09, 2024 / 2:00AM, IRON.OQ - Disc Medicine Inc at American Society of Hematology Meeting And can you provide any additional color on the evaluation of baseline light tolerance and what metrics and thresholds will be applied?

Question: Teraesa Vitelli - Scotiabank - Analyst : Great, thank you.